Befunolol

Identification

Name
Befunolol
Accession Number
DB09013
Type
Small Molecule
Groups
Experimental
Description

Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

Structure
Thumb
Synonyms
  • (RS)-1-{7-[2-hydroxy-3-(propan-2-ylamino)propoxy]- 1-benzofuran-2-yl}ethanone
Product Ingredients
IngredientUNIICASInChI Key
befunolol hydrochlorideB03Z2VY37I39543-79-8TVVTWOGRPVJKDJ-UHFFFAOYSA-N
International/Other Brands
Benfuran / Bentos (Kakenyaku Kakko) / Betaclar / Glauconex
Categories
UNII
418546MT3A
CAS number
39552-01-7
Weight
Average: 291.347
Monoisotopic: 291.14705816
Chemical Formula
C16H21NO4
InChI Key
ZPQPDBIHYCBNIG-UHFFFAOYSA-N
InChI
InChI=1S/C16H21NO4/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14/h4-7,10,13,17,19H,8-9H2,1-3H3
IUPAC Name
1-(7-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}-1-benzofuran-2-yl)ethan-1-one
SMILES
CC(C)NCC(O)COC1=CC=CC2=C1OC(=C2)C(C)=O

Pharmacology

Indication

Used in the management of open angle glaucoma. PMID: 12480285.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UBeta-1 adrenergic receptorNot AvailableHuman
UBeta-2 adrenergic receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Befunolol.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Befunolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental, Illicit
AceclofenacAceclofenac may decrease the antihypertensive activities of Befunolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Befunolol.Approved, Experimental, Investigational
AcepromazineBefunolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Befunolol.Approved
AcetohexamideBefunolol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Befunolol is combined with Acetylcholine.Approved
AcetyldigitoxinBefunolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinBefunolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Befunolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental, Investigational
AlaproclateThe serum concentration of Befunolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Befunolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Befunolol.Approved, Illicit
AlfuzosinBefunolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Befunolol.Approved, Vet Approved
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Befunolol.Experimental
AmbenoniumAmbenonium may increase the bradycardic activities of Befunolol.Approved
AmiodaroneThe therapeutic efficacy of Befunolol can be increased when used in combination with Amiodarone.Approved, Investigational
AmitrazAmitraz may increase the atrioventricular blocking (AV block) activities of Befunolol.Vet Approved
AmitriptylineBefunolol may increase the orthostatic hypotensive activities of Amitriptyline.Approved
AmobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Befunolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmoxapineBefunolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Befunolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Befunolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Befunolol.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Befunolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Befunolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Befunolol is combined with Arecoline.Experimental
AripiprazoleBefunolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved, Investigational
AsenapineBefunolol may increase the orthostatic hypotensive activities of Asenapine.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Befunolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Befunolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Befunolol.Approved, Investigational
BarbexacloneThe serum concentration of Befunolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Befunolol can be decreased when it is combined with Barbital.Illicit
BendazacBendazac may decrease the antihypertensive activities of Befunolol.Experimental
BenorilateBenorilate may decrease the antihypertensive activities of Befunolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Befunolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Befunolol.Approved
Benzylpenicilloyl PolylysineBefunolol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BethanecholThe risk or severity of adverse effects can be increased when Befunolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
BevantololBefunolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Befunolol.Experimental
BL-1020BL-1020 may increase the hypotensive activities of Befunolol.Investigational
BrexpiprazoleBefunolol may increase the orthostatic hypotensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Befunolol.Approved
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Befunolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Befunolol.Investigational
BucindololBefunolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Befunolol.Approved, Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Befunolol.Experimental
BunazosinBefunolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Befunolol.Approved, Investigational
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Befunolol.Approved
CarbamoylcholineThe risk or severity of adverse effects can be increased when Befunolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Befunolol.Experimental, Investigational
CarbutamideBefunolol may increase the hypoglycemic activities of Carbutamide.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved, Withdrawn
CarvedilolBefunolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Befunolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Befunolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Befunolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Befunolol can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Befunolol.Experimental
ChlorpromazineBefunolol may increase the orthostatic hypotensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideBefunolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Befunolol.Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Befunolol.Approved
ClozapineBefunolol may increase the orthostatic hypotensive activities of Clozapine.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Befunolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Befunolol.Approved, Investigational
CymarinBefunolol may increase the bradycardic activities of Cymarin.Experimental
DapiprazoleBefunolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
DapoxetineThe serum concentration of Befunolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Befunolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Befunolol.Approved
DeslanosideBefunolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Befunolol.Approved, Investigational
DetomidineDetomidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Vet Approved
DextroamphetamineBefunolol may increase the orthostatic hypotensive activities of Dextroamphetamine.Approved, Illicit
DichlorvosDichlorvos may increase the bradycardic activities of Befunolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Befunolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Befunolol.Approved, Investigational
DigitoxinBefunolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinBefunolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Befunolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Befunolol.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Befunolol.Approved, Investigational
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Befunolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Befunolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Befunolol.Experimental
DL-MethylephedrineDL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
DonepezilDonepezil may increase the bradycardic activities of Befunolol.Approved
DoxazosinBefunolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinBefunolol may increase the orthostatic hypotensive activities of Doxepin.Approved, Investigational
DronedaroneDronedarone may increase the bradycardic activities of Befunolol.Approved
DroperidolBefunolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Vet Approved
DroxicamDroxicam may decrease the antihypertensive activities of Befunolol.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
DuloxetineDuloxetine may increase the tachycardic activities of Befunolol.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Befunolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Befunolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Befunolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Befunolol.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Befunolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Befunolol.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Befunolol.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Befunolol.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Befunolol.Approved
EscitalopramBefunolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
EtanerceptEtanercept may decrease the antihypertensive activities of Befunolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Befunolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Befunolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Befunolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
EtoperidoneThe serum concentration of Befunolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Befunolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Befunolol.Investigational, Nutraceutical
ExisulindExisulind may decrease the antihypertensive activities of Befunolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Befunolol.Experimental
FenbufenFenbufen may decrease the antihypertensive activities of Befunolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Befunolol.Approved
FentanylFentanyl may increase the bradycardic activities of Befunolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Befunolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Befunolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Befunolol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Befunolol.Experimental
FingolimodBefunolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Befunolol is combined with Floctafenine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Befunolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Befunolol.Experimental
FluoxetineThe serum concentration of Befunolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolBefunolol may increase the orthostatic hypotensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may increase the hypotensive activities of Befunolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Befunolol.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Befunolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Befunolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Befunolol.Approved, Investigational, Nutraceutical
GitoformateBefunolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideBefunolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideBefunolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBefunolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBefunolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneBefunolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideBefunolol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideBefunolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Befunolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Befunolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
HexobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Befunolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Befunolol.Approved, Investigational
HydroxychloroquineThe metabolism of Befunolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Befunolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Befunolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Befunolol.Approved, Investigational
IloperidoneBefunolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Befunolol.Experimental
ImipramineBefunolol may increase the orthostatic hypotensive activities of Imipramine.Approved
IndalpineThe serum concentration of Befunolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Befunolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Befunolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Befunolol.Withdrawn
IndoraminBefunolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanBefunolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkBefunolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Befunolol.Experimental
IsoflurophateIsoflurophate may increase the bradycardic activities of Befunolol.Approved, Investigational, Withdrawn
IsoxicamIsoxicam may decrease the antihypertensive activities of Befunolol.Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Befunolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Befunolol.Approved
LabetalolBefunolol may increase the orthostatic hypotensive activities of Labetalol.Approved
Lanatoside CBefunolol may increase the bradycardic activities of Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the antihypertensive activities of Befunolol.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Befunolol.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Befunolol.Approved, Vet Approved
LisdexamfetamineBefunolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Befunolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Befunolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Befunolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Befunolol.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Befunolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Befunolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Befunolol.Approved
MalathionMalathion may increase the bradycardic activities of Befunolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Befunolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
MedetomidineMedetomidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Befunolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Befunolol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Befunolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Befunolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Befunolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Befunolol.Approved, Investigational
MetahexamideBefunolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Befunolol.Approved, Investigational, Withdrawn
MethacholineBefunolol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Befunolol.Investigational
MethohexitalThe serum concentration of Befunolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineBefunolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved, Investigational
MethyldopaMethyldopa may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Befunolol.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Befunolol.Approved
MethylphenobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinBefunolol may increase the bradycardic activities of Metildigoxin.Experimental
MetoclopramideMetoclopramide may increase the bradycardic activities of Befunolol.Approved, Investigational
MidodrineBefunolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Befunolol.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Befunolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Befunolol.Investigational
MofebutazoneMofebutazone may decrease the antihypertensive activities of Befunolol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Befunolol.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Befunolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Befunolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Befunolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Befunolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Befunolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
NefazodoneBefunolol may increase the orthostatic hypotensive activities of Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Befunolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Befunolol.Approved, Investigational
NicardipineBefunolol may increase the orthostatic hypotensive activities of Nicardipine.Approved, Investigational
NicergolineBefunolol may increase the orthostatic hypotensive activities of Nicergoline.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Befunolol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Befunolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Befunolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Befunolol.Approved
NiguldipineBefunolol may increase the orthostatic hypotensive activities of Niguldipine.Experimental
NimesulideNimesulide may decrease the antihypertensive activities of Befunolol.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Befunolol.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
NortriptylineBefunolol may increase the orthostatic hypotensive activities of Nortriptyline.Approved
OlanzapineBefunolol may increase the orthostatic hypotensive activities of Olanzapine.Approved, Investigational
OleandrinBefunolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Befunolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Befunolol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Befunolol.Vet Approved
OuabainBefunolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Befunolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Befunolol.Approved, Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
PalmidrolPalmidrol may decrease the antihypertensive activities of Befunolol.Experimental, Nutraceutical
ParaoxonParaoxon may increase the bradycardic activities of Befunolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Befunolol.Approved
ParoxetineThe serum concentration of Befunolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Befunolol.Approved, Investigational
PentobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerazinePerazine may increase the hypotensive activities of Befunolol.Approved, Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Befunolol.Approved
PeruvosideBefunolol may increase the bradycardic activities of Peruvoside.Experimental
PhenobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineBefunolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
PhentolamineBefunolol may increase the orthostatic hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Befunolol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Befunolol is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Befunolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Befunolol.Approved, Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Befunolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Befunolol.Experimental
PizotifenBefunolol may increase the orthostatic hypotensive activities of Pizotifen.Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Befunolol.Experimental, Investigational
PrazosinBefunolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Befunolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Befunolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Befunolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Befunolol.Experimental
PromazineBefunolol may increase the orthostatic hypotensive activities of Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Befunolol.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Befunolol.Approved, Investigational
PropafenoneThe serum concentration of Befunolol can be increased when it is combined with Propafenone.Approved
PropericiazineBefunolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
PropiomazineBefunolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Befunolol.Vet Approved
PropiverineBefunolol may increase the orthostatic hypotensive activities of Propiverine.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Befunolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Befunolol.Experimental
ProscillaridinBefunolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Befunolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Befunolol.Approved, Investigational
QuetiapineBefunolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
QuinidineBefunolol may increase the orthostatic hypotensive activities of Quinidine.Approved, Investigational
RacepinephrineRacepinephrine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Befunolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Befunolol.Approved
ReserpineReserpine may increase the hypotensive activities of Befunolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Befunolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Befunolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Befunolol can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Befunolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
RivastigmineBefunolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Befunolol.Approved, Investigational, Withdrawn
RomifidineRomifidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Vet Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
SalicylamideSalicylamide may decrease the antihypertensive activities of Befunolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Befunolol.Approved, Investigational, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Befunolol.Approved
SecobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SemapimodSemapimod may decrease the antihypertensive activities of Befunolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Befunolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Befunolol.Investigational
SertralineThe serum concentration of Befunolol can be increased when it is combined with Sertraline.Approved
SilodosinBefunolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Befunolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Befunolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Befunolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Befunolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Befunolol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Befunolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Befunolol.Experimental
TacrineTacrine may increase the bradycardic activities of Befunolol.Investigational, Withdrawn
TafenoquineThe metabolism of Befunolol can be decreased when combined with Tafenoquine.Investigational
TamsulosinBefunolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Befunolol.Investigational
TenidapTenidap may decrease the antihypertensive activities of Befunolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Befunolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Befunolol.Vet Approved
TerazosinBefunolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Befunolol.Approved
ThiamylalThe serum concentration of Befunolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Befunolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Befunolol.Withdrawn
ThiopentalThe serum concentration of Befunolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineBefunolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
ThioridazineBefunolol may increase the orthostatic hypotensive activities of Thioridazine.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Befunolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Befunolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
TolazamideBefunolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineBefunolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideBefunolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Befunolol.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Befunolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Befunolol.Approved, Investigational
TrazodoneBefunolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Befunolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Befunolol.Vet Approved
TrifluoperazineBefunolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Befunolol.Approved, Vet Approved
TrimazosinBefunolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimipramineBefunolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Befunolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Befunolol.Approved
TyrothricinTyrothricin may increase the bradycardic activities of Befunolol.Approved
UrapidilBefunolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Befunolol.Approved, Investigational, Withdrawn
VareniclineThe risk or severity of adverse effects can be increased when Befunolol is combined with Varenicline.Approved, Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Befunolol.Approved
VerapamilBefunolol may increase the orthostatic hypotensive activities of Verapamil.Approved
XylazineXylazine may increase the atrioventricular blocking (AV block) activities of Befunolol.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Befunolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Befunolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Befunolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneBefunolol may increase the orthostatic hypotensive activities of Ziprasidone.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Befunolol.Withdrawn
ZuclopenthixolBefunolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Reichl S, Muller-Goymann CC: The use of a porcine organotypic cornea construct for permeation studies from formulations containing befunolol hydrochloride. Int J Pharm. 2003 Jan 2;250(1):191-201. [PubMed:12480285]
External Links
KEGG Drug
D07496
PubChem Compound
2309
PubChem Substance
310264971
ChemSpider
2219
ChEBI
135212
ChEMBL
CHEMBL153984
Wikipedia
Befunolol
ATC Codes
S01ED06 — Befunolol

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US3853923No1971-05-131991-05-13Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)115Ito, K., Mashiko, I.,Kimura, K. and Nakanishi,T.;U.S. Patent 3,853,923; December 10.1974; assigned to Kakenyaku Kakko Co., Ltd.
Predicted Properties
PropertyValueSource
Water Solubility0.108 mg/mLALOGPS
logP1.71ALOGPS
logP1.23ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)13.92ChemAxon
pKa (Strongest Basic)9.57ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area71.7 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity79.5 m3·mol-1ChemAxon
Polarizability32.01 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzofurans
Sub Class
Not Available
Direct Parent
Benzofurans
Alternative Parents
Aryl alkyl ketones / Alkyl aryl ethers / Benzenoids / Heteroaromatic compounds / Furans / Secondary alcohols / 1,2-aminoalcohols / Oxacyclic compounds / Dialkylamines / Organopnictogen compounds
show 2 more
Substituents
Benzofuran / Aryl ketone / Aryl alkyl ketone / Alkyl aryl ether / Benzenoid / Furan / Heteroaromatic compound / 1,2-aminoalcohol / Ketone / Secondary alcohol
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Yamada Y, Takayanagi R, Tsuchiya K, Ito K, Ohtani H, Sawada Y, Iga T: Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther. 2001 Jun;17(3):235-48. [PubMed:11436944]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Yamada Y, Takayanagi R, Tsuchiya K, Ito K, Ohtani H, Sawada Y, Iga T: Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther. 2001 Jun;17(3):235-48. [PubMed:11436944]

Drug created on June 20, 2014 17:23 / Updated on July 02, 2018 20:41